How do you utilize lenalidomide maintenance in non-transplant eligible myeloma?
Does the choice of initial induction regimen affect your decision for when to employ lenalidomide maintenance?
Are there situations where you would consider stopping therapy for a patient in a VGPR or better? Does MRD testing have a role in this decision-making?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · OhioHealth
Answered on · Updated on
Maintenance is a standard of care management for both transplant eligible and transplant ineligible, regardless of type of induction regimen. Studies have shown benefit for both groups. Time to progression (PFS) almost twice as long for both groups with maintenance compared to no maintenance.
- For ...
Join for free or sign in to see the full answer